|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.68 USD | -5.96% |
|
-7.29% | +169.02% |
| 18/04 | JonesTrading Starts Rezolute With Buy Rating, $10 Price Target | MT |
| 06/03 | Rezolute, Inc. Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia | CI |
Rezolute, Inc. reported earnings results for the fourth quarter ended June 30, 2023. For the fourth quarter, the company reported net loss was USD 12.73 million compared to USD 9.42 million a year ago. Basic loss per share from continuing operations was USD 0.25 compared to USD 0.3 a year ago.
Diluted loss per share from continuing operations was USD 0.25 compared to USD 0.37 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +169.02% | 114M | |
| +5.40% | 111B | |
| +12.13% | 105B | |
| -12.61% | 22.34B | |
| -3.70% | 21.93B | |
| -6.03% | 18.59B | |
| -35.21% | 18.12B | |
| -10.82% | 16.96B | |
| +5.15% | 13.7B | |
| +37.63% | 12.45B |
REZOLUTE, INC. 
